IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-32782-3.html
   My bibliography  Save this article

Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors

Author

Listed:
  • Elisa I. Rivas

    (Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM))

  • Jenniffer Linares

    (Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM))

  • Melissa Zwick

    (Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM))

  • Andrea Gómez-Llonin

    (Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM))

  • Marc Guiu

    (Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST))

  • Anna Labernadie

    (Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute for Science and Technology (BIST))

  • Jordi Badia-Ramentol

    (Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM))

  • Anna Lladó

    (Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST))

  • Lídia Bardia

    (Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST))

  • Iván Pérez-Núñez

    (Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM))

  • Carolina Martínez-Ciarpaglini

    (Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia)

  • Noelia Tarazona

    (Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia)

  • Anna Sallent-Aragay

    (Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM))

  • Marta Garrido

    (Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM))

  • Toni Celià-Terrassa

    (Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM))

  • Octavio Burgués

    (Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia)

  • Roger R. Gomis

    (Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST))

  • Joan Albanell

    (Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
    Hospital del Mar
    Universitat Pompeu Fabra
    Centro de Investigación Biomédica en Red de Oncología (CIBERONC-ISCIII))

  • Alexandre Calon

    (Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM))

Abstract

About 50% of human epidermal growth factor receptor 2 (HER2)+ breast cancer patients do not benefit from HER2-targeted therapy and almost 20% of them relapse after treatment. Here, we conduct a detailed analysis of two independent cohorts of HER2+ breast cancer patients treated with trastuzumab to elucidate the mechanisms of resistance to anti-HER2 monoclonal antibodies. In addition, we develop a fully humanized immunocompetent model of HER2+ breast cancer recapitulating ex vivo the biological processes that associate with patients’ response to treatment. Thanks to these two approaches, we uncover a population of TGF-beta-activated cancer-associated fibroblasts (CAF) specific from tumors resistant to therapy. The presence of this cellular subset related to previously described myofibroblastic (CAF-S1) and podoplanin+ CAF subtypes in breast cancer associates with low IL2 activity. Correspondingly, we find that stroma-targeted stimulation of IL2 pathway in unresponsive tumors restores trastuzumab anti-cancer efficiency. Overall, our study underscores the therapeutic potential of exploiting the tumor microenvironment to identify and overcome mechanisms of resistance to anti-cancer treatment.

Suggested Citation

  • Elisa I. Rivas & Jenniffer Linares & Melissa Zwick & Andrea Gómez-Llonin & Marc Guiu & Anna Labernadie & Jordi Badia-Ramentol & Anna Lladó & Lídia Bardia & Iván Pérez-Núñez & Carolina Martínez-Ciarpag, 2022. "Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32782-3
    DOI: 10.1038/s41467-022-32782-3
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-32782-3
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-32782-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Floriane Pelon & Brigitte Bourachot & Yann Kieffer & Ilaria Magagna & Fanny Mermet-Meillon & Isabelle Bonnet & Ana Costa & Anne-Marie Givel & Youmna Attieh & Jorge Barbazan & Claire Bonneau & Laetitia, 2020. "Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms," Nature Communications, Nature, vol. 11(1), pages 1-20, December.
    2. Jerod L. Ptacin & Carolina E. Caffaro & Lina Ma & Kristine M. San Jose Gall & Hans R. Aerni & Nicole V. Acuff & Rob W. Herman & Yelena Pavlova & Michael J. Pena & David B. Chen & Lilia K. Koriazova & , 2021. "An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism," Nature Communications, Nature, vol. 12(1), pages 1-14, December.
    3. Kosuke Yoshihara & Maria Shahmoradgoli & Emmanuel Martínez & Rahulsimham Vegesna & Hoon Kim & Wandaliz Torres-Garcia & Victor Treviño & Hui Shen & Peter W. Laird & Douglas A. Levine & Scott L. Carter , 2013. "Inferring tumour purity and stromal and immune cell admixture from expression data," Nature Communications, Nature, vol. 4(1), pages 1-11, December.
    4. Jan Budczies & Frederick Klauschen & Bruno V Sinn & Balázs Győrffy & Wolfgang D Schmitt & Silvia Darb-Esfahani & Carsten Denkert, 2012. "Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization," PLOS ONE, Public Library of Science, vol. 7(12), pages 1-7, December.
    5. Nadim Aizarani & Antonio Saviano & Sagar & Laurent Mailly & Sarah Durand & Josip S. Herman & Patrick Pessaux & Thomas F. Baumert & Dominic Grün, 2019. "A human liver cell atlas reveals heterogeneity and epithelial progenitors," Nature, Nature, vol. 572(7768), pages 199-204, August.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Jenniffer Linares & Anna Sallent-Aragay & Jordi Badia-Ramentol & Alba Recort-Bascuas & Ana Méndez & Noemí Manero-Rupérez & Daniele Lo Re & Elisa I. Rivas & Marc Guiu & Melissa Zwick & Mar Iglesias & C, 2023. "Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy," Nature Communications, Nature, vol. 14(1), pages 1-18, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Zhongqi Fan & Xinchen Zou & Guangyi Wang & Yahui Liu & Yanfang Jiang & Haoyan Wang & Ping Zhang & Feng Wei & Xiaohong Du & Meng Wang & Xiaodong Sun & Bai Ji & Xintong Hu & Liguo Chen & Peiwen Zhou & D, 2024. "A transcriptome based molecular classification scheme for cholangiocarcinoma and subtype-derived prognostic biomarker," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    2. Dongliang Bian & Liangdong Sun & Junjie Hu & Liang Duan & Haoran Xia & Xinsheng Zhu & Fenghuan Sun & Lele Zhang & Huansha Yu & Yicheng Xiong & Zhida Huang & Deping Zhao & Nan Song & Jie Yang & Xiao Ba, 2023. "Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    3. Shaoshuai Tang & Yunzhi Wang & Rongkui Luo & Rundong Fang & Yufeng Liu & Hang Xiang & Peng Ran & Yexin Tong & Mingjun Sun & Subei Tan & Wen Huang & Jie Huang & Jiacheng Lv & Ning Xu & Zhenmei Yao & Qi, 2024. "Proteomic characterization identifies clinically relevant subgroups of soft tissue sarcoma," Nature Communications, Nature, vol. 15(1), pages 1-24, December.
    4. Franziska Hildebrandt & Alma Andersson & Sami Saarenpää & Ludvig Larsson & Noémi Van Hul & Sachie Kanatani & Jan Masek & Ewa Ellis & Antonio Barragan & Annelie Mollbrink & Emma R. Andersson & Joakim L, 2021. "Spatial Transcriptomics to define transcriptional patterns of zonation and structural components in the mouse liver," Nature Communications, Nature, vol. 12(1), pages 1-14, December.
    5. Jin Sheng & Yun-Peng Yang & Yu-Xiang Ma & Tao Qin & Zhi-Huang Hu & Shao-Dong Hong & Ting Zhou & Yan Huang & Hong-Yun Zhao & Li Zhang, 2016. "Low Prognostic Nutritional Index Correlates with Worse Survival in Patients with Advanced NSCLC following EGFR-TKIs," PLOS ONE, Public Library of Science, vol. 11(1), pages 1-12, January.
    6. Inmaculada Ruz-Maldonado & John T. Gonzalez & Hanming Zhang & Jonathan Sun & Alicia Bort & Inamul Kabir & Richard G. Kibbey & Yajaira Suárez & Daniel M. Greif & Carlos Fernández-Hernando, 2024. "Heterogeneity of hepatocyte dynamics restores liver architecture after chemical, physical or viral damage," Nature Communications, Nature, vol. 15(1), pages 1-23, December.
    7. Lucia Taraborrelli & Yasin Şenbabaoğlu & Lifen Wang & Junghyun Lim & Kerrigan Blake & Noelyn Kljavin & Sarah Gierke & Alexis Scherl & James Ziai & Erin McNamara & Mark Owyong & Shilpa Rao & Aslihan Ka, 2023. "Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    8. Erica Carolina & Yoshiki Kuse & Ayumu Okumura & Kenji Aoshima & Tomomi Tadokoro & Shinya Matsumoto & Eriko Kanai & Takashi Okumura & Toshiharu Kasai & Souichiro Yamabe & Yuji Nishikawa & Kiyoshi Yamag, 2024. "Generation of human iPSC-derived 3D bile duct within liver organoid by incorporating human iPSC-derived blood vessel," Nature Communications, Nature, vol. 15(1), pages 1-15, December.
    9. James T. Topham & Erica S. Tsang & Joanna M. Karasinska & Andrew Metcalfe & Hassan Ali & Steve E. Kalloger & Veronika Csizmok & Laura M. Williamson & Emma Titmuss & Karina Nielsen & Gian Luca Negri & , 2022. "Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma," Nature Communications, Nature, vol. 13(1), pages 1-13, December.
    10. T. Hautz & S. Salcher & M. Fodor & G. Sturm & S. Ebner & A. Mair & M. Trebo & G. Untergasser & S. Sopper & B. Cardini & A. Martowicz & J. Hofmann & S. Daum & M. Kalb & T. Resch & F. Krendl & A. Weisse, 2023. "Immune cell dynamics deconvoluted by single-cell RNA sequencing in normothermic machine perfusion of the liver," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    11. Jennifer G. Abelin & Erik J. Bergstrom & Keith D. Rivera & Hannah B. Taylor & Susan Klaeger & Charles Xu & Eva K. Verzani & C. Jackson White & Hilina B. Woldemichael & Maya Virshup & Meagan E. Olive &, 2023. "Workflow enabling deepscale immunopeptidome, proteome, ubiquitylome, phosphoproteome, and acetylome analyses of sample-limited tissues," Nature Communications, Nature, vol. 14(1), pages 1-22, December.
    12. Boshu Ouyang & Caihua Shan & Shun Shen & Xinnan Dai & Qingwang Chen & Xiaomin Su & Yongbin Cao & Xifeng Qin & Ying He & Siyu Wang & Ruizhe Xu & Ruining Hu & Leming Shi & Tun Lu & Wuli Yang & Shaojun P, 2024. "AI-powered omics-based drug pair discovery for pyroptosis therapy targeting triple-negative breast cancer," Nature Communications, Nature, vol. 15(1), pages 1-20, December.
    13. Wanzun Lin & Li Chen & Haojiong Zhang & Xianxin Qiu & Qingting Huang & Fangzhu Wan & Ziyu Le & Shikai Geng & Anlan Zhang & Sufang Qiu & Long Chen & Lin Kong & Jiade J. Lu, 2023. "Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation," Nature Communications, Nature, vol. 14(1), pages 1-22, December.
    14. Kang Wang & Ioannis Zerdes & Henrik J. Johansson & Dhifaf Sarhan & Yizhe Sun & Dimitris C. Kanellis & Emmanouil G. Sifakis & Artur Mezheyeuski & Xingrong Liu & Niklas Loman & Ingrid Hedenfalk & Jonas , 2024. "Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer," Nature Communications, Nature, vol. 15(1), pages 1-24, December.
    15. Brian D. Lehmann & Antonio Colaprico & Tiago C. Silva & Jianjiao Chen & Hanbing An & Yuguang Ban & Hanchen Huang & Lily Wang & Jamaal L. James & Justin M. Balko & Paula I. Gonzalez-Ericsson & Melinda , 2021. "Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes," Nature Communications, Nature, vol. 12(1), pages 1-18, December.
    16. B Rey deCastro, 2019. "Cumulative ROC curves for discriminating three or more ordinal outcomes with cutpoints on a shared continuous measurement scale," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-16, August.
    17. Julia M. Houthuijzen & Roebi Bruijn & Eline Burg & Anne Paulien Drenth & Ellen Wientjens & Tamara Filipovic & Esme Bullock & Chiara S. Brambillasca & Emilia M. Pulver & Marja Nieuwland & Iris Rink & F, 2023. "CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer," Nature Communications, Nature, vol. 14(1), pages 1-21, December.
    18. Aleksandr Ianevski & Anil K. Giri & Tero Aittokallio, 2022. "Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    19. Claudia Bühnemann & Simon Li & Haiyue Yu & Harriet Branford White & Karl L Schäfer & Antonio Llombart-Bosch & Isidro Machado & Piero Picci & Pancras C W Hogendoorn & Nicholas A Athanasou & J Alison No, 2014. "Quantification of the Heterogeneity of Prognostic Cellular Biomarkers in Ewing Sarcoma Using Automated Image and Random Survival Forest Analysis," PLOS ONE, Public Library of Science, vol. 9(9), pages 1-14, September.
    20. Hyungjin Kim & Chang Min Park & Bhumsuk Keam & Sang Joon Park & Miso Kim & Tae Min Kim & Dong-Wan Kim & Dae Seog Heo & Jin Mo Goo, 2017. "The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors," PLOS ONE, Public Library of Science, vol. 12(11), pages 1-13, November.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32782-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.